SCHEDULE: BlackRock Discloses 5.1% Stake in Damora Therapeutics
Schedule 13G Filing
BlackRock, Inc. has reported beneficial ownership of 5.1% of Damora Therapeutics Inc.'s common stock as of June 30, 2026.
Summary
- BlackRock, Inc. has filed a Schedule 13G, indicating it beneficially owns 3,143,576 shares of Damora Therapeutics Inc. common stock.
- This ownership represents 5.1% of the class of securities.
- The filing date for this event is June 30, 2026.
- BlackRock, Inc. has sole voting power over 3,072,238 shares and sole dispositive power over 3,143,576 shares.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates institutional interest but provides no operational or financial details about the company itself.
Positives
- BlackRock's investment signals confidence in Damora Therapeutics' potential.
- A significant institutional investor like BlackRock can bring stability and credibility to the company.
Negatives
- The filing does not contain any negative financial or operational information about Damora Therapeutics.
Risks
- The filing does not explicitly mention any risks associated with Damora Therapeutics.
Future Outlook
The filing does not contain any forward-looking statements or guidance from Damora Therapeutics.
Industry Context
StockSavvy.ai notes that institutional investment in biotechnology and therapeutics companies is a common strategy for large asset managers like BlackRock, seeking growth opportunities in the healthcare sector.
Stakeholder Impact
- Shareholders: May view BlackRock's investment as a positive signal, potentially increasing investor confidence.
- Management: May see the investment as validation of their strategy, but also face increased scrutiny from a significant institutional holder.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney dated April 30, 2023, revoked by the new power of attorney. |
| 2025-01-21 | Date of execution of the new Power of Attorney by BlackRock, Inc. |
| 2026-06-30 | Date of event requiring the filing of Schedule 13G. |
| 2026-07-28 | Date of signature on the Schedule 13G filing by Spencer Fleming, Managing Director. |
Keywords
Damora Therapeutics, BlackRock, Schedule 13G, Institutional Investor, Beneficial Ownership, Common Stock, Healthcare, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.